OnKure director granted 22,350 stock options

OnKure Therapeutics, Inc. reported that director Liam Ratcliffe received a grant of 22,350 stock options, each representing the right to buy one share of Class A Common Stock at an exercise price of $4.14 per share.

Accepted by SEC EDGAR 08/11/2026 - 04:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. reported that director Liam Ratcliffe received a grant of 22,350 stock options, each representing the right to buy one share of Class A Common Stock at an exercise price of $4.14 per share. All 22,350 options will vest on the earlier of June 4, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Ratcliffe holds 22,350 derivative securities of this option award, which is scheduled to expire on August 6, 2036.

Insider Trade Summary

Grant/Award: 22,350 shares

Grant/Award 1 txn

Insider Ratcliffe Liam

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	22,350	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 22,350 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

Key Figures

Options granted: 22,350 options Exercise price: $4.14 per share Expiration date: August 6, 2036 +3 more

6 metrics

Options granted 22,350 options Stock Option (right to buy) granted to director Liam Ratcliffe

Exercise price $4.14 per share Conversion or exercise price for the 22,350 stock options

Expiration date August 6, 2036 Scheduled expiration of the granted stock options

Underlying shares 22,350 shares Class A Common Stock underlying the option award

Post-transaction holdings 22,350 derivative securities Total options held in this award after the transaction

Vesting date trigger June 4, 2027 100% vesting on earlier of this date or day prior to next annual meeting

Key Terms

Stock Option (right to buy), exercise price, vesting, Class A Common Stock

4 terms

Stock Option (right to buy) financial

"security_title is listed as Stock Option (right to buy)"

exercise price financial

"conversion or exercise price is stated as 4.1400 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"100% of the shares subject to the option will vest on the earlier of June 4, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Class A Common Stock financial

"underlying security title is identified as Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OnKure Therapeutics (OKUR) director Liam Ratcliffe receive in this Form 4?

Director Liam Ratcliffe received a grant of 22,350 stock options to purchase Class A Common Stock at an exercise price of $4.14 per share, expiring on August 6, 2036, subject to vesting conditions.

What is the vesting schedule for Liam Ratcliffe’s new OKUR stock options?

All 22,350 options will vest 100% on the earlier of June 4, 2027 or the day prior to OnKure’s next annual stockholder meeting, conditioned on Ratcliffe continuing as a service provider through the vesting date.

What is the exercise price of the stock options granted to Liam Ratcliffe at OnKure Therapeutics (OKUR)?

The granted stock options have an exercise price of $4.14 per share for 22,350 underlying shares of Class A Common Stock, as disclosed in the Form 4 derivative transaction details.

How many OnKure Therapeutics (OKUR) options does Liam Ratcliffe hold after this transaction?

Following this award, Liam Ratcliffe’s reported holding for this option grant is 22,350 derivative securities, each for one share of Class A Common Stock, all held as direct ownership according to the Form 4.

When do Liam Ratcliffe’s OnKure Therapeutics (OKUR) options expire?

The stock options granted to Liam Ratcliffe are scheduled to expire on August 6, 2036. They become exercisable after vesting, which occurs in full on the specified earlier vesting date condition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ratcliffe Liam

(Last) (First) (Middle)

C/O ONKURE THEREAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.14	08/07/2026		A		22,350		(1)	08/06/2036	Class A Common Stock	22,350	$0	22,350	D

Explanation of Responses:

1. 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.

	/s/ Rogan Nunn, by power of attorney	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)